SELLAS Life Sciences stock surged 15% on August 21, 2026, driven by growing investor focus on the company’s pivotal Phase 3 REGAL trial nearing completion, according to analysis from Quiver Quantitative. The biotech company’s lead cancer therapy candidate, galinpepimut-S (GPS), is being evaluated as a maintenance treatment for acute myeloid leukemia patients in remission.
The REGAL trial had reached 78 of 80 required events as of May 11, 2026, leaving only two milestones before the company triggers final analysis and announces topline results, according to SELLAS’s first-quarter earnings report. The company expects the topline readout in the fourth quarter of 2026.
GPS is a multivalent WT1 peptide vaccine designed to stimulate a strong T-cell-mediated immune response in AML patients who have achieved complete remission following second-line salvage therapy. According to research published in peer-reviewed journals, the vaccine works by targeting WT1, a protein frequently overexpressed in leukemia cells, helping the immune system recognize and attack remaining cancer cells.
The trial’s primary success threshold is approximately 12.6 months median overall survival for GPS versus 8.1 months with standard treatment, SELLAS disclosed. Earlier Phase 2 data in a similar elderly AML population with a median age of 74 showed a median overall survival of 21 months, providing initial evidence for the drug’s potential, according to CEO Angelos Stergiou in recent conference presentations.
Institutional investors have been building positions ahead of the trial readout. State Street added 4.6 million shares in the second quarter of 2026, increasing its stake by 54.8%, while BlackRock added 2.9 million shares, according to Quiver Quantitative’s institutional holdings data. The company reported $138.3 million in cash and cash equivalents as of June 30, 2026, providing runway to fund operations while awaiting the critical trial results.
Short interest in SLS stock stood at roughly 28-30% of the float as of late July, meaning roughly 55 million shares were sold short. This significant short position can amplify gains when buying pressure builds, contributing to the stock’s volatile upside moves, according to market analysis from Quiver Quantitative and trading platforms.
The surge reflects a broader pattern in biotech investing, where clinical trial catalysts drive substantial stock movements. Small-cap biotech companies typically experience higher abnormal returns on the day of trial announcements compared to larger pharmaceutical firms, according to research on sponsor stock reactions to clinical trial outcomes.
Sources
- Quiver Quantitative — SLS stock up 15.3% on August 21, 2026; analysis of institutional buying and short interest; Q2 2026 cash position of $138.3 million
- SELLAS Life Sciences investor relations — May 12, 2026 Q1 earnings: REGAL trial at 78 of 80 events; August 11, 2026 Q2 update confirming approach to 80th event threshold
- StockTwits — CEO commentary on GPS median survival in Phase 2 elderly AML population (21 months); trial success threshold (12.6 months vs 8.1 months); upcoming TD Cowen Oncology Innovation Summit participation
- PubMed/PMC — GPS mechanism: WT1 peptide vaccine inducing T-cell-mediated immune response in AML maintenance therapy
- Yahoo Finance — SLS stock three-week gain streak; management entering quiet period after 80th event announcement
